Article Details
Retrieved on: 2025-03-08 16:05:14
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses the reaffirmed positive opinion of lecanemab, an anti-amyloid drug for Alzheimer's, by the European Medicines Agency. It highlights trial results and contrasts it with other orphan drugs like aducanumab and donanemab.
Article found on: www.neurologylive.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here